Abstract:Background Most adoptive cell therapies (ACTs) suffer from an inability to control the therapeutic cell’s behavior following its transplantation into a patient. Thus, efforts to inhibit, activate, differentiate or terminate an ACT after patient reinfusion can be futile, because the required drug adversely affects other cells in the patient. Methods We describe here a two domain fusion receptor composed of a ligand-binding domain linked to a recycling domain that allows constitutive internalization and trafficking of the fusion receptor back to the cell surface. Because the ligand-binding domain is designed to bind a ligand not normally present in humans, any drug conjugated to this ligand will bind and endocytose selectively into the ACT. Results In two embodiments of our strategy, we fuse the chronically endocytosing domain of human folate receptor alpha to either a murine scFv that binds fluorescein or human FK506 binding protein that binds FK506, thereby creating a fusion receptor composed of largely human components. We then create the ligand-targeted drug by conjugating any desired drug to either fluorescein or FK506, thereby generating a ligand-drug conjugate with ~10 -9 M affinity for its fusion receptor. Using these tools, we demonstrate that CAR T cell activities can be sensitively tuned down or turned off in vitro as well as tightly controlled following their reinfusion into tumor-bearing mice. Conclusions We suggest this ‘chimeric endocytosing receptor’ can be exploited to manipulate not only CAR T cells but other ACTs following their reinfusion into patients. With efforts to develop ACTs to treat diseases including diabetes, heart failure, osteoarthritis, cancer and sickle cell anemia accelerating, we argue an ability to manipulate ACT activities postinfusion will be important.

Engineering genetic devices for in vivo control of therapeutic T cell activity triggered by the dietary molecule resveratrol

Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56

Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety

Engineering programmable CAR-T cells with tunable controls as fail-safe mechanisms during cancer immunotherapy

Engineering light-controllable CAR T cells for cancer immunotherapy

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Breakthroughs in synthetic controlling strategies for precision in CAR-T therapy

Enhancing the Safety of CAR-T Cell Therapy: Synthetic Genetic Switch for Spatiotemporal Control.

Aptamer-Based Nongenetic Reprogramming of CARs Enables Flexible Modulation of T Cell-Mediated Tumor Immunotherapy

Pharmacological control of CAR T cells through CRISPR-driven rapamycin resistance

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy

Abstract 3579: RegCAR-TTM: Enabling Next-Generation CAR-T Therapy

Sensitive manipulation of CAR T cell activity using a chimeric endocytosing receptor

A New Insight in Chimeric Antigen Receptor-Engineered T Cells for Cancer Immunotherapy

Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization

Conditional control of chimeric antigen receptor T-cell activity through a destabilizing domain switch and its chemical ligand

Engineering self-propelled tumor-infiltrating CAR T cells using synthetic velocity receptors

Click CAR-T cell engineering for robustly boosting cell immunotherapy in blood and subcutaneous xenograft tumor

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing

Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy

Mechanisms and strategies for safe chimeric antigen receptor T‐cell activity control